Emcure Q2 PAT up 25%, domestic and international biz drive 13% revenue rise

The company's revenue from operations rose to Rs 2,269.8 crore, a 13.4 per cent increase from Rs 2,001.9 crore in Q2FY25

Emcure Pharmaceuticals on Tuesday reported a 25 per cent year-on-year (Y-o-Y) jump in its consolidated net profit at ₹251.3 crore for the second quarter of 2025-26 (Q2 FY26), up from ₹201.5 crore in the same period last year, an impressive showing which the company attributed to its strong performance in both the domestic and international markets.

 

The company’s revenue from operations rose to ₹2,269.8 crore, a 13.4 per cent increase from ₹2,001.9 crore in Q2FY25.

 

Sequentially, net profit rose by 17 per cent, while revenue from operations grew by 8 per cent from ₹215 crore and ₹2,101 crore, respectively.

 

 

Satish Mehta, chief executive officer (CEO) and managing director, Emcure Pharmaceuticals, said that the company delivered a very strong performance in Q2, with all business segments contributing to growth.

 

Emcure’s domestic business grew by 10.6 per cent Y-o-Y to ₹1,031 crore, led by strong performance across all its key therapies and aided by new initiatives.

 

“Domestic business remains a key focus and we continue to enhance our product portfolio and strengthen the team for the business,” the company said in a regulatory filing on the bourses.

 

As a part of this vision, Emcure announced a strategic partnership with Novo Nordisk to launch Poviztra, a 2.4 milligram (mg) form of injectable semaglutide in India. The company had also completed the acquisition of a 20.42 per cent minority stake in its subsidiary Zuventus Healthcare in this quarter. 

 

In the international market, Emcure recorded a 15.8 per cent growth to ₹1,238 crore in the September quarter, up from ₹ 1,069 crore in the same period last year.

 

This was led by a 22.7 per cent Y-o-Y revenue rise in the European Union (EU) market segment to ₹444 crore in Q1 FY26 from ₹362 crore, aided by new launches and ramp-up by UK based Manx Pharma.

 

Emcure’s Canada business also reported a 17.5 per cent Y-o-Y growth in revenue to ₹348 crore in Q1FY26 from ₹296 crore in Q1 FY25.

 

“Rest of the world business also saw sustained momentum led by non-ARV business,” Emcure said.

 

The company said that its key priorities moving forward will be improving margins through new product launches and operating efficiencies.

 

“We continue to augment our portfolio in all our focus markets though in-licensing and in-house developments,” Mehta added.

 

On Thursday, Emcure Pharma’s stock fell by 4.22 per cent to ₹1,367.35 apiece on the Bombay Stock Exchange (BSE).